• Tamoxifen in Research: SERM-Driven Gene Knockout & Cancer St

  2026-06-19

  Tamoxifen, a selective estrogen receptor modulator, is pivotal for CreER-mediated gene knockout, advanced breast cancer research, and modulation of cellular signaling. This guide delivers actionable protocols, troubleshooting strategies, and deep integration of recent advances—anchored by APExBIO’s high-purity Tamoxifen.

• AG-221 (Enasidenib): Metabolic Dependencies and Strategic ID

  2026-06-19

  Discover how AG-221 (Enasidenib) reveals new metabolic dependencies in acute myeloid leukemia research. This in-depth analysis explores IDH2 mutation-driven vulnerabilities, the impact of CD44-mediated rewiring, and advanced strategies for overcoming resistance.

• Streptavidin-Cy3: Advancing Biotin Detection in NPC Metastas

  2026-06-18

  Explore the strategic use of Streptavidin-Cy3 in high-sensitivity biotin detection, with mechanistic insights into nasopharyngeal carcinoma (NPC) metastasis research. This article bridges advanced biotin labeling workflows with translational needs, critically evaluating current evidence and offering forward-looking guidance for researchers targeting super-enhancer RNA mechanisms.

• SB 431542: Applied Workflows for ALK5 Inhibition in Stem Cel

  2026-06-18

  SB 431542 is a highly selective ALK5 inhibitor that empowers robust dissection of TGF-β signaling in stem cell, cancer, and immunology workflows. This article translates bench research and reference protocols into practical guidance for optimizing experimental outcomes and troubleshooting common pitfalls with APExBIO’s SB 431542.

• Prostaglandin E2 in Inflammation Research: Workflows & Innov

  2026-06-17

  Prostaglandin E2 (PGE2) is a pivotal tool for dissecting immune regulation and inflammation mechanisms, offering reproducible, high-purity performance in both cell-based and translational studies. This guide delivers advanced workflow enhancements, troubleshooting strategies, and practical insights inspired by recent breakthroughs in humoral immunity.

• Merimepodib (VX-497): Selective Oral IMPDH Inhibitor for Res

  2026-06-17

  Merimepodib (VX-497) is a selective, orally bioavailable IMPDH inhibitor with validated immunosuppressive and antiviral activities. It disrupts guanine nucleotide synthesis, suppresses lymphocyte proliferation, and impairs replication of RNA viruses in diverse models. These properties make Merimepodib a pivotal reagent for cancer, immunology, and virology research.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate

  2026-06-16

  This study introduces a streamlined, multi-step protocol for synthesizing deuterium-labeled degarelix acetate, a critical internal standard for clinical and metabolic research. The work advances isotope labeling approaches for robust pharmacokinetic and androgen-related disease studies.

• Plerixafor (AMD3100): Mechanistic Insights and Protocols in

  2026-06-16

  Explore the advanced mechanistic roles of Plerixafor (AMD3100) in cancer metastasis inhibition and hematopoietic stem cell mobilization. This article delivers practical protocol guidance, deep scientific analysis, and unique insights on leveraging AMD3100 for cutting-edge research.

• Molnupiravir Blocks Bourbon Virus in Mice: Insights for Anti

  2026-06-15

  This study demonstrates that molnupiravir, an orally available nucleoside analogue, suppresses Bourbon virus infection and related pathology in a mouse model. The findings provide foundational evidence supporting the evaluation of nucleoside analogue antivirals for emerging tick-borne RNA viruses, with direct implications for translational antiviral research.

• AMPK’s Dual Role in Autophagy: Revisiting Energy Stress Resp

  2026-06-15

  This article analyzes a recent study that challenges the established view of AMPK as a universal activator of autophagy under glucose starvation. The paper demonstrates that AMPK actually suppresses autophagy initiation via ULK1 inhibition, while preserving autophagy machinery for recovery, offering nuanced insight into cellular energy stress responses.

• Scenario-Driven Solutions with Mifepristone (RU486) in Cell

  2026-06-14

  This article provides an evidence-based, scenario-driven guide for deploying Mifepristone (RU486) (SKU B1511) in cell viability, proliferation, and cytotoxicity workflows. By addressing real laboratory challenges—from inconsistent data to vendor selection—it demonstrates how APExBIO’s high-purity Mifepristone supports reproducible, high-impact research.

• Tumor-Targeted PAD4 Inhibitors Disrupt NETs for Antitumor Ef

  2026-06-13

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors that selectively target tumor cells and neutrophils, disrupting the PAD4-H3cit-NETs pathway to inhibit tumor growth and metastasis in vivo. The findings define a strategy for high-specificity antitumor therapy with minimized off-target toxicity.

• Remdesivir (GS-5734): Advanced Antiviral Workflows & Insight

  2026-06-12

  Remdesivir (GS-5734) stands at the forefront of coronavirus antiviral research, offering validated nanomolar efficacy and workflow flexibility for both in vitro and in vivo applications. This article unpacks protocol enhancements, troubleshooting techniques, and translational insights for maximizing assay performance in RNA virus studies.

• Redefining AMPK’s Role in Autophagy: New Insights into Energ

  2026-06-12

  This article analyzes a recent study that overturns the prevailing model of AMPK as a direct inducer of autophagy in glucose-starved cells. By demonstrating that AMPK actually inhibits ULK1 and autophagy initiation during energy stress, the research provides a crucial update for studies of autophagy regulation and cellular homeostasis.

• Structural Insights into the Nipah Virus Polymerase Complex

  2026-06-11

  This study reports the high-resolution structures of the Nipah virus L-P polymerase complex, illuminating the molecular organization and interactions critical for viral RNA replication and transcription. These findings provide a structural foundation for future antiviral development targeting the Nipah virus replication machinery.

16054 records 1/1071 page Next 12345 下5页 Last page